

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1654  
Examiner : Gudibande, Satyanarayan R.  
Applicant(s) : Nancy Jean Britten  
Serial Number : 10/687,986  
Filed : October 17, 2003  
Confirmation No. : 1367  
Docket No. : PC27098  
For : DISPERSIBLE PHARMACEUTICAL COMPOSITIONS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Dear Sir:

Claims 1-48 are pending in the present application. The claims have been subject to a restriction/election of species requirement. Applicants elect the Group I claims, that is, claims 1-40. In response to the election of species requirement Applicants elect ceftiofur hydrochloride as the antibacterial substance. Applicants also elect Labrafil M-19944CS, which is a polyglycolized glyceride having oleic acid as the main fatty acid component, as the amphipathic oil, and cottonseed oil as the non-aqueous carrier. In response to the election of species requirement Applicants elect, with traverse, the mammary gland as the single organ. Applicants respectfully suggest that since pharmaceutical composition claims 1-40 have been elected for prosecution, an election of species requirement relating only to claims which have been withdrawn under the restriction requirement is inappropriate.

**PATENT**/Docket No. PC27098

Appl. No. 10/687,986


Filing Date: October 17, 2003

Response to Restriction Requirement of February 7, 2008

If the Examiner believes that personal communications will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

Dated: FEB 28, 2008

  
John H. Engelmann  
Registration No. 28,075  
Pfizer Inc.  
7000 Portage Road  
Kalamazoo, MI 49001  
Tel. (269) 833-2532  
Fax (269) 833-8897